Voyager Therapeutics, Inc. Earnings Per Share (Diluted)
Voyager Therapeutics, Inc. (VYGR) reported Earnings Per Share (Diluted) of -$0.40 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- Voyager Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.40.
- Voyager Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.47.
- Voyager Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.47.
- Voyager Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.47.
- Voyager Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$2.04.
- Voyager Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$1.13, a 138.05% decline from fiscal 2023.
- Voyager Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was $2.97.
- Voyager Therapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$1.21.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.40 10-Q · filed 2026-08-06 | -$0.87 10-Q · filed 2026-08-06 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.47 10-Q · filed 2026-05-07 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.41 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.98 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.51 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.04 10-K · filed 2026-03-09 |
| 2025-09-30 | -$0.47 10-Q · filed 2025-11-10 | -$1.04 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.57 10-Q · filed 2025-11-10 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.57 10-Q · filed 2026-08-06 | -$1.10 10-Q · filed 2026-08-06 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.85 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.53 10-Q · filed 2026-05-07 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.13 10-K · filed 2026-03-09 |
| 2024-09-30 | -$0.16 10-Q · filed 2025-11-10 | -$0.33 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.53 10-Q · filed 2025-11-10 | $0.46 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-06-30 | -$0.18 10-Q · filed 2025-08-06 | -$0.37 10-Q · filed 2025-08-06 | $0.63 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.17 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-03-31 | -$0.20 10-Q · filed 2025-05-06 | $0.84 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.38 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-12-31 | $1.12 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.65 derived: net income ÷ weighted average shares · filed 2026-04-28 | $0.18 derived: net income ÷ weighted average shares · filed 2026-04-28 | $2.97 10-K · filed 2026-03-09 |
| 2023-09-30 | -$0.59 10-Q · filed 2024-11-12 | -$1.10 derived: net income ÷ weighted average shares · filed 2024-11-12 | $1.78 10-Q · filed 2024-11-12 | $1.24 derived: net income ÷ weighted average shares · filed 2025-03-11 |
| 2023-06-30 | -$0.51 10-Q · filed 2024-08-06 | $2.33 10-Q · filed 2024-08-06 | $1.89 derived: net income ÷ weighted average shares · filed 2025-03-11 | $2.34 derived: net income ÷ weighted average shares · filed 2025-03-11 |
| 2023-03-31 | $2.94 10-Q · filed 2024-05-13 | $2.49 derived: net income ÷ weighted average shares · filed 2025-03-11 | $2.94 derived: net income ÷ weighted average shares · filed 2025-03-11 | $2.50 derived: net income ÷ weighted average shares · filed 2025-03-11 |
| 2022-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.15 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$0.65 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$1.21 10-K · filed 2025-03-11 |
| 2022-09-30 | $0.45 10-Q · filed 2023-11-06 | -$0.04 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$0.59 10-Q · filed 2023-11-06 | -$0.44 derived: net income ÷ weighted average shares · filed 2024-02-28 |
| 2022-06-30 | -$0.50 10-Q · filed 2023-08-03 | -$1.06 10-Q · filed 2023-08-03 | -$0.91 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.58 derived: net income ÷ weighted average shares · filed 2024-02-28 |
| 2022-03-31 | -$0.56 10-Q · filed 2023-05-09 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.08 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.87 derived: net income ÷ weighted average shares · filed 2024-02-28 |
| 2021-12-31 | $0.15 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$0.51 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.31 derived: net income ÷ weighted average shares · filed 2024-02-28 | -$1.89 10-K · filed 2024-02-28 |
| 2021-09-30 | -$0.67 10-Q · filed 2022-11-08 | -$1.47 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$2.04 10-Q · filed 2022-11-08 | -$2.48 derived: net income ÷ weighted average shares · filed 2023-03-07 |
| 2021-06-30 | -$0.80 10-Q · filed 2022-08-04 | -$1.38 10-Q · filed 2022-08-04 | -$1.81 derived: net income ÷ weighted average shares · filed 2023-03-07 | $0.48 derived: net income ÷ weighted average shares · filed 2023-03-07 |
| 2021-03-31 | -$0.58 10-Q · filed 2022-05-04 | -$1.01 derived: net income ÷ weighted average shares · filed 2023-03-07 | $1.29 derived: net income ÷ weighted average shares · filed 2023-03-07 | $1.06 derived: net income ÷ weighted average shares · filed 2023-03-07 |
| 2020-12-31 | -$0.43 derived: net income ÷ weighted average shares · filed 2023-03-07 | $1.87 derived: net income ÷ weighted average shares · filed 2023-03-07 | $1.64 derived: net income ÷ weighted average shares · filed 2023-03-07 | $0.98 10-K · filed 2023-03-07 |
| 2020-09-30 | $2.27 10-Q · filed 2021-11-02 | $2.06 derived: net income ÷ weighted average shares · filed 2021-11-02 | $1.40 10-Q · filed 2021-11-02 | |
| 2020-06-30 | -$0.23 10-Q · filed 2020-08-10 | -$0.89 10-Q · filed 2020-08-10 | ||
| 2019-12-31 | -$0.34 derived: net income ÷ weighted average shares · filed 2022-03-08 | -$0.75 derived: net income ÷ weighted average shares · filed 2022-03-08 | -$0.44 derived: net income ÷ weighted average shares · filed 2022-03-08 | -$1.21 10-K · filed 2022-03-08 |
| 2019-09-30 | -$0.41 10-Q · filed 2020-11-09 | -$0.10 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$0.87 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.29 10-Q · filed 2020-08-10 | -$0.46 10-Q · filed 2020-08-10 | ||
| 2018-12-31 | -$2.75 10-K · filed 2021-02-25 | |||
| 2018-06-30 | -$0.80 10-Q · filed 2019-08-09 | -$1.43 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |